Fibrinolytics and Antifibrinolytics

1. Front Matter

   Pages I-XXI

   PDF

2. The Fibrinolytic Process

   1. Front Matter

      Pages 1-1

      PDF

   2. Biochemistry of the Factors of the Fibrinolytic System

      • H. Landmann

      Pages 3-48

   3. Fibrinogen and Fibrin Formation

      • B. Blombäck

      Pages 49-79

   4. Fibrinogen and Fibrin Degradation Products

      • M. Kopeć, Z. S. Latallo

      Pages 81-105

   5. The Measurement of Fibrinolytic Activities

      • I. M. Nilsson, U. Hedner, M. Pandolfi

      Pages 107-134

3. Activators of Fibrinolysis

   1. Front Matter

      Pages 135-135

      PDF

   2. Biochemistry of Streptokinase

      • F. B. Taylor Jr., P. C. Comp

      Pages 137-149

   3. Pharmacology of Streptokinase

      • H.-P. Klöcking

      Pages 151-177

   4. Clinical Use of Streptokinase

      • G. Vogel

      Pages 179-207

   5. Urokinase

      • F. Duckert

      Pages 209-237

   6. Synthetic Fibrinolytic Agents Induction of Fibrinolytic Activity In Vitro

      • K. N. von Kaulla

      Pages 239-272

   7. Indirect Fibrinolytic Agents

      • P. C. Desnoyers

      Pages 273-314

4. Fibrinolytically Active Enzymes

   1. Front Matter

      Pages 315-315

      PDF

   2. Plasmin

      • K. C. Robbins

      Pages 317-336

   3. Fungal Proteases

      • W. H. E. Roschlau

      Pages 337-450

   4. Defibrinogenation with Thrombin-Like Snake Venom Enzymes

      • K. Stocker

      Pages 451-484

5. Antifibrinolytics

   1. Front Matter

      Pages 485-485

      PDF

   2. Naturally Occurring Inhibitors of Fibrinolysis

      • F. Markwardt

      Pages 487-509

   3. Synthetic Inhibitors of Fibrinolysis

      • F. Markwardt

      Pages 511-577

Disturbances of haemostasis and thromboembolic disorders still constitute a great problem in clinical practice. Increasing insight into the mechanism of blood coagula­ tion has led to more effective therapy and prophylaxis. Particularly, the understand­ ing of the biochemistry of fibrinolysis has provided possibilities for the pharma­ cological interference of these processes, which has resulted in effective haemostatic agents and useful antithrombotic ones. The development of antifibrinolytics for interfering with pathological fibrinolytic processes is nearly complete and has led to the development of drugs essential to the therapy of hyperfibrinolytic bleeding. The search for fibrinolytics for dissolving intravascular thrombi has led to highly effective compounds. This development is still under way and promising results are hoped. Spontaneous dissolution of blood clots is a phenomenon which was described a century ago. First investigations of this process assured that there is in the organism a system capable of removing the fibrin which is formed during blood coagulation after it has fulfilled its physiological function. This fibrinolytic system is specifically adapted to the degradation of insoluble fibrin into soluble degradation products. In the past 30 years, thorough investigation of this system has clarified the fibrinolytic process, its physiological role and its meaning as a pathogenetic principle. A good knowledge of these processes is required for an understanding of the effects and side effects of fibrinolytics and antifibrinolytics, which comprise the basis of methods for the detection of fibrinolytic processes in the organism and of the control of therapy with these drugs.

• Antifibrinolytikum
• Fibrinolytikum
• biochemistry
• chemistry
• research
• therapy

• Institut für Pharmakologie und Toxikologie, Medizinische Akademie Erfurt, Erfurt, German Democratic Republic

  F. Markwardt

Policies and ethics